Trial Profile
A Randomized Double-blind Active-controlled Trial of Canakinumab Versus Triamcinolone Acetonide on Reducing the Proportion of Patients With Any New Gouty Arthritis Flare(s) in Patients With Chronic Kidney Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 24 Apr 2017
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary) ; Triamcinolone
- Indications Gouty arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 15 May 2012 New trial record